CohBar is a California-based clinical stage biotechnology company that develops mitochondria-based therapeutics (MBTs) for chronic and age-related diseases. The company's lead clinical candidate is CB4211, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. CohBar also has preclinical programs including CB5138 analogs for fibrotic diseases and CB5064 analogs for COVID-19 associated ARDS.